Evidence for the use of chemotherapy in breast cancer

International Journal of Clinical Oncology

Volumn 7, Issue 4, 2002, Pages 254-264

  Nabholtz, Jean Mare ^a   Reese, David ^b,c,d   Lindsay, Mary Ann ^b,c,d   Riva, Alessandro ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Breast Cancer International Res Grp   (United States)

^c Breast Cancer Intl Research Group   (Canada)

^d Breast Cancer Research Institute   (France)

Author keywords

Breast cancer; Capecitabine; Chemotherapy; Docetaxel; Paclitaxel; Predictive factors; Prognostic factors; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FADROZOLE; FLUOROURACIL; HER 2 RECEPTOR PROTEIN; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; PROTEIN; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; DRUG ANTAGONISM; DRUG INDUCED DISEASE; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; HUMAN; METASTASIS; MONOTHERAPY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036692495     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200037     Document Type: Conference Paper

References (83)

1. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
2. A systematic overview of chemotherapy effects in breast cancer
3. Polychemotherapy for early breast cancer: An overview of the randomised trials
4. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumours: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
5. Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer
6. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23
7. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
8. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
9. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup Trial Int 0102
10. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group
11. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 Randomized Trial
12. Improved disease-free survival (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node positive primary breast cancer (BC)
13. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
14. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
15. Further evaluation of intensified and increased dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
16. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: An update
17. Evolution in the treatment of advanced breast cancer
18. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
19. Drug therapy: Paclitaxel (Taxol)
20. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
21. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)
22. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342
23. Randomized trial of 3-h versus 24-h infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26
24. Final results: Randomized phase III trial of paclitaxel by 3-HR versus 96-HR infusion in patients (pts) with met breast cancer (MBC): The long and short of it
25. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer
26. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over
27. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An Intergroup trial
28. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
29. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer
30. Prospective randomized trial of docetaxel versus dixorubicin in patients with metastatic breast cancer
31. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
32. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomized phase III study with crossover on progression by the Scandinavian Breast Group
33. Taxotere versus 5-fluorouracil + Navelbine in patients with metastatic breast cancer as second line chemotherapy
34. Docetaxel administered on a weekly basis for metastatic breast cancer
35. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer
36. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial
37. Paclitaxel by 3-h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-sequence-finding study
38. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
39. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
40. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Results of a randomized phase III multicenter trial
41. Doxorubicin (A)/taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study
42. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group
43. UKCCR trial of epirubicin and cyclophosphamide (EC) vs epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC)
44. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
45. Phase II study of docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer
46. Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group study E1196
47. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer
48. Doxorubicin (DOX) and Taxotere® (TXT): A pharmacokinetic (PK) study of the combination in advanced breast cancer
49. Taxotere (T) does not change the pharmacokinetic (PK) profile of doxorubicine and doxorubicinol (Dx-ol)
50. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC
51. A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)
52. Epirubicin/docetaxel (ET) versus 5FU/epirubicin/cyclophosphamide (FAC) combinations as first line chemotherapy in patients with metastatic breast cancer [MBC]
53. Adjuvant therapy for breast cancer, November 1-3, 2001
54. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP B-27
55. New options for outpatient chemotherapy - The role of oral fluoropyrimidines
56. Capecitabine: Preclinical pharmacology studies
57. The angiogenic factor platelet-derived endothelial growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium
58. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
59. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results
60. TEX (Taxotere, epirubicin, and Xeloda) regimen as first line chemotherapy in advanced breast cancer
61. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
62. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
63. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow up
64. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
65. Efficacy and safety of trastuzumab as a single agent in the treatment of HER2-overexpressing metastatic breast cancer
66. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
67. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization
68. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for the treatment of human breast cancer
69. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression
70. Results of two open-label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene
71. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
72. Meeting highlights: International consensus panel on the treatment of primary breast cancer
73. Adjuvant therapy for breast cancer
74. Tamoxifen for early breast cancer: An overview of the randomized trials
75. Endocrine therapy in the treatment of metastatic breast cancer
76. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
77. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
78. Serum HER-2/neu and response to megace vs an aromatase inhibitor
79. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer
80. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
81. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
82. HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide